Ignyta's (RXDX) Entrectinib Granted FDA Orphan Drug Designation
- Futures fall as high oil prices stoke inflation worries; Tesla falls
- Musk Failed to Convince Twitter (TWTR) to Lower the Deal Price - Reports
- Citi Says Buy US and UK Equities, Sees 18% Upside in Global Equities to End-2023
- Dollar wavers with ECB minutes and Friday's U.S. jobs data in focus
- UBS Sees Over 25% Upside Potential in Apple Shares as iPhone Demand Remains Strong
Ignyta (NASDAQ: RXDX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta’s lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC).
“Entrectinib has the potential to address unmet needs of patients with rare cancers, and we will continue to aggressively pursue our clinical development program for entrectinib in solid tumors for the benefit of these patients,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “We are pleased to receive from FDA this second orphan drug designation for non-small cell lung cancer, in addition to neuroblastoma, which can potentially provide additional avenues for creating value for our stockholders through our entrectinib clinical program.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Mallinckrodt (MNKPF) Appoints Susan Silbermann to its Board
- Cytosorbents (CTSO) Awarded $4.3M Contract by the U.S. DoD to Develop HemoDefend-BGA
- Integer Holdings Corp (ITGR) Provides 2022 Update
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!